These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32554618)

  • 41. A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis.
    Valente M; Colucci M; Vegni V; Croce V; Bellan C; Rossi G; Gibilisco G; Frongia F; Guazzo R; Ghiribelli C; Bargagli E; Savelli V; Ravara M; Sani T; Simonetti E; Maio M; Calabrò L; Di Giacomo AM
    Onco Targets Ther; 2024; 17():673-681. PubMed ID: 39188308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.
    Reid P; Liew DF; Akruwala R; Bass AR; Chan KK
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34526389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
    Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Balasubramanian A; Onggo J; Gunjur A; John T; Parakh S
    Clin Lung Cancer; 2021 Mar; 22(2):74-82. PubMed ID: 33414053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis.
    Wang PM; Zhang ZW; Zhang S; Xing Q; Zhao ZY; Lin QH; Shen LH; Xia ZL; Li FF; Zhu B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):8019-8026. PubMed ID: 36944820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
    Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
    Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
    Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.
    Hu Q; Wang S; Ma L; Sun Z; Liu Z; Deng S; Zhou J
    J Cell Mol Med; 2024 Mar; 28(5):e17895. PubMed ID: 37525480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
    Bilger G; Girard N; Doubre H; Levra MG; Giroux-Leprieur E; Giraud F; Decroisette C; Carton M; Massiani MA
    Cancer Immunol Immunother; 2022 Jul; 71(7):1719-1731. PubMed ID: 34821950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
    Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
    Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.